Abstract: Methods for treating retroviral infection or inhibiting HIV integrase in target cells or in a patient involve administering to target cells or to a patient in need of treatment an effective amount of at least one having a disulfonamide scaffold which is represented by the formula: wherein, independent of each other, each X independently represents hydrocarbyl, halogeno, amino, substituted amino, or alkoxy, wherein substituted amino is represented by —NR3,R4 wherein R3 and R4, are not both hydrogen and independently represent alkyl or alkenyl, n is an integer of 0, 1, 2, or 3, each Y independently represents hydrocarbyl, halogeno, amino, substituted amino or alkoxy, wherein substituted amino is represented by —NR3,R4 wherein R3 and R4, are not both hydrogen and independently represent alkyl or alkenyl, m is an integer of 0, 1, 2, or 3, and R represents di-valent hydrocarbyl, substituted or unsubstituted.

Abstract: Methods for treating retroviral infection or inhibiting HIV integrase in target cells or in a patient involve administering to target cells or to a patient in need of treatment an effective amount of at least one having a disulfonamide scaffold which is represented by the formula: wherein, independent of each other, each X independently represents hydrocarbyl, halogeno, amino, substituted amino, or alkoxy, wherein substituted amino is represented by —NR3,R4 wherein R3 and R4, are not both hydrogen and independently represent alkyl or alkenyl, n is an integer of 0, 1, 2, or 3, each Y independently represents hydrocarbyl, halogeno, amino, substituted amino or alkoxy,wherein substituted amino is represented by —NR3,R4 wherein R3 and R4, are not both hydrogen and independently represent alkyl or alkenyl, m is an integer of 0, 1, 2, or 3, and R represents di-valent hydrocarbyl, substituted or unsubstituted.

Abstract: A method for treating against HIV, such as by inhibiting HIV integrase, in target cells or in a patient involves administering to target cells or to a patient in need of treatment an effective amount of at least one compound having an N-indol heteroarylcarboxamide scaffold which compound is represented by the formula: wherein, independent of each other, R independently represents hydrocarbyl, halogeno, amino, substituted amino, or alkoxy, R1 represents di-valent hydrocarbyl, substituted or unsubstituted, and R2 represents an ether moiety.

Abstract: The present invention is directed to compounds useful in the treatment of diseases associated with prenylation of proteins and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising same, and to methods for inhibiting protein prenylation in an organism using the same.